Pharmaresearch Joins Hands with China's CCM to Accelerate Local Market Expansion
Maximizing Synergy Through Joint Venture
"Broad Cooperation Including Local Product Development"
Pharmaresearch announced on September 21 that it has signed a strategic Memorandum of Understanding (MOU) for cooperation with Chinese cosmetics company CCM to expand Rejuran Cosmetic's presence in the Chinese market.
Founded in 2002, CCM is an investment-driven cosmetics brand management company in China, owning multiple brands that enjoy high recognition both domestically and internationally. Last year, CCM posted sales of about 9.178 billion yuan (approximately 1.9 trillion won), ranking second in sales among Chinese cosmetics groups.
Pharmaresearch and CCM officials are taking a commemorative photo after signing a business agreement. Pharmaresearch
View original imageThe two companies plan to maximize their synergy by establishing a joint venture (JV) in the future. Pharmaresearch aims to expand its cooperation beyond supplying finished Rejuran Cosmetic products to also include developing localized products and utilizing the Rejuran Cosmetic brand.
Hot Picks Today
"3821% Returns" "Better Than Stocks": 30s and 40s Flock to the Market, Secondhand Trading Surges
- [Exclusive] "Nvidia Researchers to Work in Yangjae"... LG Electronics to Establish 'Joint Robotics Development Base'
- "Often Ate Malatang and Chinese Food..." Shock Over the Reality of Chinese Bamboo Shoots Mass-Produced With Sulfur
- "I’ll Take This, Please"... Buying the Last Lottery Ticket Brings a Jackpot
- "Surprisingly Real, Perfect Like AI" -- Global Media Praise Korean Fencer's Beauty
A Pharmaresearch representative said, "In the United States, we are strengthening our local production base by acquiring cosmetics contract development and manufacturing organization (CDMO) company CG USA. In China, we plan to accelerate commercialization by partnering with CCM, which has expertise in product research and development (R&D), brand building, and business operations."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.